Aleem Gangjee

Undergraduate:

• 232 Basic Pharmacology (University of Pittsburgh, 1983)
• 309 Biochemistry and Nutrition
• 310 Analysis of Drug Substances
• 313 Medicinal Chemistry & Natural Products
• 314 Medicinal Chemistry & Natural Products
• 352 Foundations of Pharmacology and Medicinal Chemistry
• 421 Medicinal Chemistry
• 427 Biomedical Sciences/Therapeutics VI: Pulmonary,
• Oncology and Hematology Module
• 429 Biomedical Sciences and Therapeutics VIII

Graduate:

• 522 Spectral Methods
• 523 Advanced Medicinal Chemistry I
• 524 Advanced Medicinal Chemistry II
• 623 Selected Topics in Medicinal Chemistry
• 671 Chemistry of Heterocyclic Compounds
• 527 Advanced Medicinal Chemistry

 

• Ranked first in the graduating M.S. Class of 1971, Organic Chemistry, Indian Institute of Technology.
• International Student Scholarship, University of Iowa, 1971-75.
• Research Assistantship, Graduate College, University of Iowa, 1971-75.
• Award for Outstanding Academic Achievement Graduate College, University of Iowa, 1973.
• Phi Lambda Upsilon, Chemistry Honor Society, 1975.
• Postdoctoral Trainee Fellowship National Cancer Institute training grant at SUNY, Buffalo, 1976-1979.
• The American Men and Women of Science, 1979.
• Rho Chi, Pharmacy Honor Society, 1980.
• The Society of Sigma XI, 1981.
• Starter Grant, Faculty Research and Scholarship Award, Duquesne University, April 1982.
• The New York Academy of Science, 1982.
• President, Duquesne Sigma Xi Club, 1983.
• Runner-up Duquesne Man of the Year, 1985-86.
• Commencement Speaker, Pharmacy Class of 1988.
• Duquesne University Presidential Award for Faculty Excellence in Scholarship, 1988.
• School of Pharmacy Teacher of the Year Award, 1988.
• Shannon Award, NIH, 1991.
• Who's Who in American Education, 1992.
• National Institutes of Health (NIH) consultant.
• Duquesne University School of Pharmacy Award for Excellence in Research, 1995.
• Who's Who in Medicine and Healthcare, 1996.
• Elected to the American Association for Cancer Research, 1996.
• National Institutes of Health, BNP-1 Special Emphasis Pane Study Sectionl, 1996.
• Duquesne University School of Pharmacy Award for Excellence in Teaching, 1997.
• Duquesne University Presidential Award for Faculty Excellence in Teaching, 1997.
• Awarded 30 US patents; one European patent.
• World Health Organization invited participant in collaborative research, 1998.
• Granted the title of School of Pharmacy Distinguished Professor, 1998.
• NIH National Cancer Institute Study Section Experimental Therapeutics I, 1999-2003.
• Chosen as a N.C.P.A. Member's Favorite Professor, 2000.
• Editorial Advisory Board Member, Current Medicinal Chemistry, Anti-Cancer Agents, 2001-present.
• Ad-Hoc Member: National Institutes of Health, Center for Scientific Review, AIDS and Related Research, 2002-2003.
• Ad-Hoc Member: National Institutes of Health, Center for Scientific Review, AIDS and
• AIDS Related Research Integrated Review Group (AARR), AIDS and AIDS Related Research Study Section, 2003-2004.
• Ad-Hoc Member: National Institutes of Health, Center for Scientific Review, Oncologic
• Sciences Integrated Review Group, Drug Discovery & Molecular Pharmacology (DMP) Study Section, 2003-2004.
• Editorial Board of Medicinal Chemistry Reviews - Online, 2004-2006.
• Member of The Honor Society of Phi Kappa Phi, 2007.
• Recipient of the President's Award for Faculty Excellence in Scholarship, September 2008.
• Member: Editorial Advisory Board, Journal of Medicinal Chemistry, 2008-2012.
• Received the President's Award for Faculty Excellence in Scholarship, Sept. 2008.
• Adrian Van Kaam, C.S.Sp., Endowed Chair in Scholarly Excellence, 2010-2015.
• Chairperson: National Institutes of Health, Center for Scientific Review Special Emphasis Panel, ZRG1 OTC-K (04) Cancer Therapeutics Study Section; Feb. 17, 2011.
• 2012 Avis Distinguished visiting Professor at the College of Pharmacy, University of Tennessee, Memphis, TN, April 23-24, 2012.
• Recipient of the 2012 Research Achievement Award in Drug Discovery and Development Interface, American Association of Pharmaceutical Scientists, (AAPS), Oct. 14, 2012.
• Received the President's Award for Faculty Excellence in Scholarship, Sept. 2014.

• Title: Therapeutic Targeting of Mitochondrial C1 Metabolism The major goal is the synthesis and evaluation of classical antifolates targeted to the SHMT 1 and 2 along with selective tumor transport and purine synthesis inhibition as anticancer agents.
  Agency: National Institute of Health, National Cancer Institute
  Time: 01/01/2021 – 12/31/2025
  Responsibility: Principal Investigator
  Amount: $3,000,000 plus
• Title: Novel Cytoskeletal Stabilizers as Potential Treatments for Limbic Lewy Body Disorders The goal of this project is to test the potency and efficacy of novel microtubule stabilizers in cellular and animal models of Lewy body disease.
  Agency: National Institute of Health, National Institute of Ageing
  Time: 09/01/2020 – 08/30/2024
  Responsibility: Principal Investigator
  Amount: $379,499
• Title: Small Molecule Microtubule Targeting Agents for Pancreatic Cancer
  Agency: Commonwealth Universal research Enhancement (PA CURE)
  Time: 06/01/2018 - 05/31/2022
  Responsibility: Principal Investigator
  Amount: $112,997
• Title: Stabilizing the Cytoskeleton in Lewy Body Disease With Novel Bicyclic Microtubule Effectors
  Agency: Samuel and Emma Winters Foundation
  Time: 07/01/2019 - 06/30/2020
  Responsibility: co-PI with Dr. Rehana Leak
  Amount: $11,020.00
• Title: Quelling Parkinson's Pathology with Novel Tricyclic Heterocycles that Stabilize the Microtubules of the Cellular Skeleton
  Agency: Leach Foundation
  Time: 07/01/2019 - 06/30/2021
  Responsibility: co-PI with Dr. Rehana Leak
  Amount: $25,000.00

Patents:

• Gangjee, A. US 9,556,198 B2. Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof. Jan. 31, 2017.
• Gangjee, A. US 9,624,178 B2. Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antimitotic and/or Antitumor Activity Methods of Use Thereof. Apr. 18, 2017.
• Gangjee, A. and Matherly, L. H. US 9,650,384 B2. Substituted Pyrimidine Compounds and Methods of Use and Manufacture. May 16, 2017.
• Gangjee, A. US 9,688,690 B2. Pyrimidine Compounds and Pyrimido Indole Compounds and methods of Use. Jun. 27, 2017.
• Gangjee, A. US 9,732,090 B2. Bicyclic and Tricyclic Pyrimidine Tryosine Kinase Inhibitors with Antitubulin Activity and Methods of Treating a Patient. Aug. 15, 2017.
• Gangjee, A. US 9,777,012 B2. Substituted Furo[2,3-d]pyrimidines as Multi-Targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents. Oct. 3, 2017.
• Gangjee, A. US 9,802,955 B2. Tricyclic Compounds Having Antimitotic and/or Antitumor activity and methods of Use Thereof. Oct. 31, 2017. Gangjee. A. US 9,896,455 B2. Tricyclic Compounds Having Cytostatic and/or Cytotoxic Activity and Methods of Use Thereof. Feb. 20, 2018.
• Gangjee, A. US 9,987,283 B2. Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use thereof. Jun. 5, 2018.
• Gangjee, A. US 9,994,586 B2. Monocyclic, Thieno, Pyrido, and Pyrrolo Pyrimidine Compounds and Methods of Use and Manufacture of the Same. Jun. 12, 2018.
• Gangjee, A. and Matherly, L. H. US 10,000,498 B2. Selective Proton Coupled Folate Transporter and Folate Receptor and GARFTase Inhibitor Compounds and Methods of Using the Same. Jun. 19, 2018.
• Gangjee, A. US 10,072,019 B2. Substituted Pyrrolo, -Furano, and Cyclopentylpyrimidines Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof. Sept. 11, 2018.
• Gangjee, A. and Matherly, L. H. US 10,167,287 B2. Substituted Pyrimidine Compounds and Methods of Use and Manufacture. Jan. 1, 2019.
• Gangjee, A. US 10,189,853 B2. Conformationally Restricted 4-Substituted 2,6-Dimethylfuro[2,3-d]pyrimidines as Anti-Tumor Agents. Jan. 29, 2019.
• Gangjee, A. US 10,208,051 B2. Tricyclic Compounds Having Cytostatic and/or Cytotoxic Activity and Methods of Use Thereof. Feb. 19, 2019.
• Gangjee, A. US 10,233,194 B2. Pyrimidine Compounds and Pyrimido Indole Compounds and Methods of Use. Mar. 19, 2019.
• Gangjee, A. US 10,239,880 B2. Cyclopenta[d]pyrimidines and Substituted Cyclopenta[d]pyrimidines as Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines as Tubulin Inhibitors and Pyrrolopyrimidines as Targeted Antifolates and Tubulin and Multiple Receptor Tyrosine Kinase Inhibition and Antitumor Agents. Mar. 26, 2019.
• Gangjee, A. US 10,358,450 B2. Substituted Bicyclic Pyrimidine Compounds with Tubulin and Multiple Receptor Inhibition. Jul. 23, 2019.
• Gangjee, A. US 10,385,064 B2. Bicyclic and Tricyclic Pyrimidine Tyrosine Kinase Inhibitors with Antitubulin Activity and Methods of Treating a Patient. Aug. 20, 2019.
• Gangjee, A. US 10,414,777 B2. Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Method of Use Thereof. Sept. 17, 2019.
• Gangjee, A. US 10,457,688 B2. Monocyclic Thieno, Pyrido, and Pyrrolo Pyrimidine Compounds and Methods of Use and Manufacture of Same. Oct. 29, 2019.
• Gangjee, A. US 10,464,944 B2. Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof. Nov. 5, 2019.
• Gangjee, A. US 10,538,527 B2. Cyclopenta[d]pyrimidines and Substituted Cyclopenta[d]-pyrimidines as Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines as Tubulin Inhibitors and Pyrrolopyrimidines as Targeted Antifolates and Tubulin and Multiple Receptor Tyrosine Kinase Inhibition and Antitumor Agents. Jan. 21, 2020.
• Gangjee, A. US 10,577,377 B2. Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof. Mar. 3, 2020.